Oncology Drugs - Japan

Japan

The projected revenue for the Oncology Drugs market in Japan is expected to reach ¥US$8.95bn in 2024.
This indicates a promising growth potential for the country's oncology drugs industry.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2028) of 13.84%, leading to a market volume of ¥US$15.03bn by 2028.
When compared globally, it is noteworthy that United States is projected to generate the highest revenue in the oncology drugs market, with an estimated value of US$114,600.00m in 2024.
This highlights the dominant position of the United States in the global oncology drugs market.
Japan is at the forefront of innovative oncology drug research and development, striving to improve patient outcomes and revolutionize cancer treatment.

Key regions: Germany, India, United Kingdom, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in Japan has experienced significant growth in recent years.

Customer preferences: Cancer is one of the leading causes of death in Japan, and as such, demand for oncology drugs has been on the rise. Patients in Japan prefer to receive the latest and most advanced treatments available, which has driven demand for innovative oncology drugs.

Trends in the market: The Oncology Drugs market in Japan has seen a shift towards targeted therapies and immunotherapies. This trend is driven by the desire to provide more personalized treatment options for patients. Additionally, the Japanese government has implemented policies to accelerate the approval process for oncology drugs, which has led to an increase in the number of drugs available on the market.

Local special circumstances: Japan has an aging population, which has contributed to the high incidence of cancer in the country. Additionally, Japan has a well-developed healthcare system that provides universal coverage, which has made it easier for patients to access oncology treatments. The Japanese government has also implemented policies to promote the development of new oncology drugs, which has created a favorable environment for drug manufacturers.

Underlying macroeconomic factors: Japan is the third-largest economy in the world and has a high standard of living. The country has a well-developed healthcare system and invests heavily in research and development. These factors have contributed to the growth of the Oncology Drugs market in Japan. Additionally, the Japanese government has implemented policies to promote innovation in the pharmaceutical industry, which has created a favorable environment for drug manufacturers.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.